Xalud Therapeutics prioritizes gene therapies, with ALS now the focus and osteoarthritis on partner path
Xalud Therapeutics has shifted its internal plans, sending its lead non-viral gene therapy on the partnering path, elevating a preclinical ALS program and letting employees go.
The company recently laid off employees, per an employee whose LinkedIn profile says they were Xalud’s director of regulatory and quality compliance. The former employee called it a “major shock” and said a “number of my colleagues” were impacted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
